Much talked-about at this year's ASH meeting, the CD33-targeting antibody-drug conjugate SGN-CD33A (33A) from Seattle Genetics Inc. faltered as the FDA put clinical holds on phase I and phase I/II trials in acute myeloid leukemia, though enrollment in the phase III CASCADE study continues.